Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVI 816

Next Previous
Drug Profile

MVI 816

Alternative Names: PAP Vaccine - Madison Vaccines; pTVG-HP; pTVG-HP Plasmid DNA Vaccine

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Madison Vaccines
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 27 Jul 2023 Madison Vaccines and University of Wisconsin completes a phase I/II trial in Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal) (NCT02499835)
  • 13 Sep 2022 Bristol-Myers Squibb discontinued phase II trial in Prostate cancer in USA (NCT03600350)
  • 28 Sep 2021 MVI 816 is still in phase II trials for Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top